GLP-1 Receptor Agonist Suite

Proposed Therapy

Baseline Weight (kg)

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

Initiating Glucagon-Like Peptide-1 (GLP-1) receptor agonists for Type 2 Diabetes Mellitus or obesity

Guiding safe and tolerable dose escalation (titration) to minimize gastrointestinal side effects

Determining the maximum tolerated or target therapeutic dose for weight loss and glycemic control

Managing dose adjustments during periods of significant gastrointestinal distress

Patient Population

Adults prescribed GLP-1 RAs (e.g., Semaglutide, Liraglutide, Dulaglutide, Tirzepatide) for either glycemic control (HbA1c lowering) or chronic weight management. Excludes patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

How it Works

Common Titration Schedules (Subcutaneous)

Semaglutide (Ozempic/Wegovy)	Start 0.25 mg weekly x 4 weeks. Increase to 0.5 mg x 4 weeks. Then 1.0 mg x 4 weeks. Max: 2.0 mg (Ozempic) or 2.4 mg (Wegovy).
Tirzepatide (Mounjaro/Zepbound)	Start 2.5 mg weekly x 4 weeks. Increase by 2.5 mg every 4 weeks. Max: 15 mg weekly.
Liraglutide (Victoza/Saxenda)	Start 0.6 mg daily. Increase by 0.6 mg daily every 1 week. Max: 1.8 mg (Victoza) or 3.0 mg (Saxenda).
Dulaglutide (Trulicity)	Start 0.75 mg weekly x 4 weeks. Increase to 1.5 mg weekly. May increase to 3.0 mg then 4.5 mg every 4 weeks if needed.

Last Comprehensive Review: 2026-07-17

Recent Journal Updates

British J HaematologyJul 22, 2026

Immunoglobulin replacement after chimeric antigen receptor T‐cell therapy in large B‐cell lymphoma with hypogammaglobulinaemia: Secondary Center for International Blood and Marrow Transplant Research analysis

Clinical Context

We think this might be relevant to the clinical guidance for GLP-1 Receptor Agonist Titration Schedule.

WHO NewsJul 15, 2026

Global childhood immunization coverage inches forward despite conflict and hesitancy – UNICEF, WHO

Clinical Context

We think this might be relevant to the clinical guidance for GLP-1 Receptor Agonist Titration Schedule.

British J Clinical PharmacologyJul 15, 2026

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

Clinical Context

We think this might be relevant to the clinical guidance for GLP-1 Receptor Agonist Titration Schedule.

GLP-1 Receptor Agonist Suite

When to Use

When to Use

Patient Population

How it Works

Common Titration Schedules (Subcutaneous)

Clinical Pearls

Clinical Pearl

Known Limitations

Next Steps

Actionable Clinical Management

The Evidence

Primary Reference

Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes.

Recent Journal Updates

GLP-1 Receptor Agonist Suite

When to Use

When to Use

Patient Population

How it Works

Common Titration Schedules (Subcutaneous)

Clinical Pearls

Clinical Pearl

Known Limitations

Next Steps

Actionable Clinical Management

The Evidence

Primary Reference

Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes.

Recent Journal Updates